Wall Street brokerages forecast that Aratana Therapeutics, Inc. (NASDAQ:PETX) will post earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Aratana Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.19). Aratana Therapeutics reported earnings of ($0.35) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 34.3%. The firm is expected to report its next earnings results on Monday, March 12th.

On average, analysts expect that Aratana Therapeutics will report full-year earnings of ($1.03) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.99). For the next year, analysts anticipate that the company will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.71) to ($0.10). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03. The business had revenue of $6.16 million during the quarter, compared to analysts’ expectations of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The firm’s revenue for the quarter was up 1440.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) EPS.

PETX has been the subject of a number of recent research reports. BidaskClub cut Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Lake Street Capital lowered their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 25th. ValuEngine lowered shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Jefferies Group restated a “buy” rating and issued a $8.00 price target on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Thursday, November 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Aratana Therapeutics presently has an average rating of “Hold” and a consensus price target of $8.75.

In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Ernst Heinen sold 10,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $6.25, for a total transaction of $62,500.00. Following the completion of the sale, the insider now owns 130,994 shares in the company, valued at $818,712.50. The disclosure for this sale can be found here. Insiders sold a total of 1,127,032 shares of company stock worth $6,622,391 over the last 90 days. Company insiders own 5.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of PETX. American International Group Inc. lifted its holdings in shares of Aratana Therapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,354 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Aratana Therapeutics by 7.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,200 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in Aratana Therapeutics by 17.9% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,883 shares during the last quarter. Voya Investment Management LLC lifted its holdings in Aratana Therapeutics by 22.7% during the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 3,610 shares during the last quarter. Finally, Ray Gerald L & Associates Ltd. lifted its holdings in Aratana Therapeutics by 0.8% during the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 73.95% of the company’s stock.

Aratana Therapeutics (PETX) traded up $0.08 during midday trading on Wednesday, reaching $5.34. The company’s stock had a trading volume of 580,500 shares, compared to its average volume of 416,782. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.42 and a quick ratio of 3.08. Aratana Therapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $8.63.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/0-23-earnings-per-share-expected-for-aratana-therapeutics-inc-petx-this-quarter.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.